ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019
Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 102 citations in OpenAlex.
- Genomic characterization of uterine adenomatoid tumors reveals recurrent alterations in KMT5A and KMT2C.Clinical epigenetics · 2026Article
- Cellular Plasticity in Malignant Transformation: Mesothelial Cells.Pathobiology : journal of immunopathology, molecular and cellular biology · 2026Review
- TRAF7-Mutated Fibromyxoid Spindle Cell Tumor of Bone: An Osseous Case Expanding the Spectrum of TRAF7-Mutated Tumors With Over 20 Years Clinical Follow-Up.Genes, chromosomes & cancer · 2026Article
- Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- The genetics of cancer heterogeneity and mesothelioma.Frontiers in oncology · 2026Review
- TRAF7 in signaling and disease: emerging mechanisms and clinical implications.Molecular medicine (Cambridge, Mass.) · 2025Review
- Prognostic Role of L1CAM in Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Peritoneal Mesothelial Tumors.Annals of surgical oncology · 2024Article
- TheMicrobiology spectrum · 2024Article
- Well-Differentiated Papillary Mesothelial Tumor of the Scrotum with Suspicious Invasion.Diagnostics (Basel, Switzerland) · 2024Article
- A case report of typical well-differentiated papillary mesothelial tumor diagnosed by internal thoracoscopy and literature review.Frontiers in oncology · 2024Article
- Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.Virchows Archiv : an international journal of pathology · 2023Article
- Very Rare Peritoneal Surface Malignancies.Indian journal of surgical oncology · 2023Article
- Adenomatoid tumors of ovary mimicking malignancy: report of 2 cases and literature review.BMC women's health · 2022Review
- Co-Localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series.Annals of surgical oncology · 2022Article
- Synchronous Jejunal Sarcomatoid Carcinoma and Incidentally Associated Localized Peritoneal Malignant Mesothelioma.Cureus · 2022Article
- The Role of Fast-Cycling Atypical RHO GTPases in Cancer.Cancers · 2022Review
- Solid papillary mesothelial tumor.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights.Frontiers in oncology · 2022Review
- Adenomatoid tumours of the gastrointestinal tract - a case-series and review of the literature.Histopathology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Well-differentiated papillary mesothelioma is an uncommon mesothelial neoplasm that most frequently arises in the peritoneal cavity of women of reproductive age. Whereas malignant mesothelioma is an aggressive tumor associated with poor outcome, well-differentiated papillary mesothelioma typically exhibits indolent behavior. However, histologically differentiating between these two entities can be challenging, necessitating the development of distinguishing biomarkers. While the genetic alterations that drive malignant mesothelioma have recently been determined, the molecular pathogenesis of well-differentiated papillary mesothelioma is unknown. Here we performed genomic profiling on a cohort of ten well-differentiated papillary mesothelioma of the peritoneum. We identified that all tumors harbored somatic missense mutations in either the TRAF7 or CDC42 genes, and lacked alterations involving BAP1, NF2, CDKN2A, DDX3X, SETD2, and ALK that are frequent in malignant mesothelioma. We recently identified that another mesothelial neoplasm, adenomatoid tumor of the genital tract, is genetically defined by somatic missense mutations in the TRAF7 gene, indicating a shared molecular pathogenesis between well-differentiated papillary mesothelioma and adenomatoid tumors. To the best of our knowledge, well-differentiated papillary mesothelioma is the first human tumor type found to harbor recurrent mutations in the CDC42 gene, which encodes a Rho family GTPase. Immunohistochemistry demonstrated intact BAP1 expression in all cases of well-differentiated papillary mesothelioma, indicating that this is a reliable marker for distinguishing well-differentiated papillary mesothelioma from malignant mesotheliomas that frequently display loss of expression. Additionally, all well-differentiated papillary mesothelioma demonstrated robust expression of L1 cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation, similar to that observed in adenomatoid tumors. In contrast, we have previously shown that L1CAM staining is not observed in normal mesothelial cells and malignant mesotheliomas of the peritoneum. Together, these studies demonstrate that well-differentiated papillary mesothelioma is genetically defined by mutually exclusive mutations in TRAF7 and CDC42 that molecularly distinguish this entity from malignant mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.